ERBB2 and neoplasm: Next, we compared outcomes within this cohort of 334 women who were deemed to be chemotherapy candidates: 98.2% of the women in this cohort had T1b or T1c tumours, 26.6% had HER2-positive tumours, and 14.1% had triple-negative tumours.